ArticleJournal of pharmacopuncture2026
Article in Journal of pharmacopuncture, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Diabetes mellitus is a progressive metabolic disorder broadly classified into insulin-deficient (type 1) and insulin-resistant (type 2) forms. Both forms ultimately lead to chronic hyperglycemia and pancreatic dysfunction, posing a major global health burden. Limitations associated with the long-term use of conventional antidiabetic drugs have encouraged investigation of plant-based treatments that may offer safer therapeutic benefits. Although Cinnamon species have traditionally been used to manage metabolic disorders, evidence from solvent-fraction studies demonstrating their antidiabetic efficacy remains limited. Methods: This study evaluated the antidiabetic activity of ethyl acetate fractions obtained from Results: Both fractions were safe up to 2,000 mg/kg. STZ-induced diabetic rats showed weight loss, hyperglycemia, impaired glucose metabolism, and pancreatic β-cell damage. Treatment with both fractions dose-dependently lowered fasting blood glucose and improved glucose tolerance. Conclusion: The ethyl acetate fractions of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.